Tegoprubart in Islet Transplantation for Type 1 Diabetes
Tegoprubart (AT-1501) is an anti-CD40L monoclonal antibody being investigated as an immunosuppressive agent for pancreatic islet transplantation in adults with type 1 diabetes who have severe metabolic instability, hypoglycemia unawareness, or end-stage renal disease requiring kidney transplantation. 1
What Tegoprubart Is and How It Works
Tegoprubart is an engineered anti-CD40 ligand (CD40L) antibody specifically designed to prevent the thromboembolic complications that plagued earlier anti-CD40L antibodies. The engineering reduced binding to Fcγ receptors on platelets while preserving the critical CD40L blockade needed for immunosuppression 1. This costimulatory blockade prevents T-cell and B-cell activation, which is essential for preventing both allograft rejection and potentially the autoimmune destruction of transplanted islets.
Clinical Trial Evidence and Outcomes
Preclinical Success
In nonhuman primate models, tegoprubart demonstrated remarkable efficacy:
- As monotherapy, it achieved long-term survival of both intrahepatic islet allografts (cynomolgus macaques) and kidney allografts (rhesus macaques) 1
- Compared to conventional immunosuppression, tegoprubart-treated animals showed higher C-peptide levels, better weight gain, and reduced cytomegalovirus reactivation 1
- These results provided strong justification for human trials
Current Clinical Development
Tegoprubart has progressed to human trials, with safety data from a Phase 2A study in amyotrophic lateral sclerosis patients (different indication) showing it is well-tolerated with dose-dependent target engagement 2. The most common adverse events were fatigue (25.9%), falls (22.2%), headaches (20.4%), and muscle spasms (11.1%), though these may be disease-specific 2.
Recent 2026 evidence suggests tegoprubart is being considered as adjunct immunomodulation for gene-edited hypoimmune islets, indicating its continued relevance in the diabetes transplantation field 3.
Patient Eligibility Criteria
Based on ADA guidelines and clinical practice, adults eligible for islet transplantation must meet all three criteria 4:
- Frequent, acute, severe metabolic complications requiring medical attention (hypoglycemia, marked hyperglycemia, ketoacidosis)
- Incapacitating clinical and emotional problems with exogenous insulin therapy
- Consistent failure of insulin-based management to prevent acute complications
Additional Screening Requirements
Before enrollment, patients must undergo assessment for 5:
- Negative C-peptide (positive C-peptide is an exclusion)
- Adequate kidney function (creatinine and microalbuminuria assessment)
- No liver disorders (alcohol-related or iron overload)
- No active pregnancy plans
- Absence of HFE heterozygosity complications
For patients with established end-stage renal disease who have had or plan kidney transplantation, islet-after-kidney transplantation is appropriate since the pancreas addition does not jeopardize patient survival and may improve kidney survival 4.
Advantages Over Conventional Immunosuppression
The tegoprubart approach offers several theoretical advantages:
- Reduced toxicity profile compared to traditional triple immunosuppression (tacrolimus, mycophenolate mofetil, prednisolone) 6
- Lower infection risk, particularly CMV reactivation 1
- Better metabolic outcomes with higher C-peptide preservation 1
- Engineered safety to avoid thromboembolic complications that ended earlier CD40L antibody development 1
Critical Limitations and Caveats
Long-Term Durability Remains Uncertain
The central unanswered question is whether short-term immune evasion translates to durable long-term graft survival 3. Even with the Edmonton protocol using conventional immunosuppression, only 44% of patients achieved insulin independence at 1 year, and 76% of those required insulin again by 2 years 7. Whether tegoprubart improves these outcomes requires longer follow-up.
Theoretical Long-Term Vulnerabilities
Several mechanisms may cause delayed graft failure 3:
- Indirect allorecognition and non-HLA antibody formation
- Persistent autoreactive immune memory
- β-cell stress-induced neoantigen formation
- Viral infection susceptibility
Practical Considerations
- Islet transplantation should only occur at tertiary care centers with active kidney transplant programs and multidisciplinary evaluation protocols 4
- Lifelong immunosuppression remains necessary even with tegoprubart, though the regimen may be less toxic 4, 1
- Patient motivation and proper counseling are critical—in one series, 16 of 41 patients (39%) declined to proceed after initial information, with 6 preferring insulin pump therapy instead 5
Current Status
Tegoprubart represents a promising evolution in islet transplantation immunosuppression, with strong preclinical data supporting its safety and efficacy 1. However, it remains investigational and should only be used within controlled clinical trial settings 4. The drug has received FDA attention (based on 2026 labeling references), suggesting regulatory progress, though specific approval status for islet transplantation requires verification through active clinical trial registries.
Durable success will likely require combining tegoprubart with other strategies such as metabolic support or additional immunomodulation rather than relying on it as monotherapy 3.